Cellular gene expression altered by human cytomegalovirus: global monitoring with oligonucleotide arrays.

Mechanistic insights to viral replication and pathogenesis generally have come from the analysis of viral gene products, either by studying their biochemical activities and interactions individually or by creating mutant viruses and analyzing their phenotype. Now it is possible to identify and catalog the host cell genes whose mRNA levels change in response to a pathogen. We have used DNA array technology to monitor the level of approximately 6,600 human mRNAs in uninfected as compared with human cytomegalovirus-infected cells. The level of 258 mRNAs changed by a factor of 4 or more before the onset of viral DNA replication. Several of these mRNAs encode gene products that might play key roles in virus-induced pathogenesis, identifying them as intriguing targets for further study.

[1]  L. Frenkel,et al.  Clinical anophthalmia associated with congenital cytomegalovirus infection. , 1980, American journal of ophthalmology.

[2]  S. Plotkin,et al.  Comparative virulence and immunogenicity of the Towne strain and a nonattenuated strain of cytomegalovirus. , 1984, Annals of internal medicine.

[3]  J. Sissons,et al.  Monocyte-derived inhibitor of interleukin 1 induced by human cytomegalovirus , 1985, Transactions of the Association of American Physicians.

[4]  G. Hayward,et al.  trans-activation and autoregulation of gene expression by the immediate-early region 2 gene products of human cytomegalovirus , 1988, Journal of virology.

[5]  G. Rice,et al.  Cytomegalovirus infection of peripheral blood mononuclear cells: effects on interleukin-1 and -2 production and responsiveness , 1988, Journal of virology.

[6]  H. O'Donoghue,et al.  Autoantibodies to cardiac myosin in mouse cytomegalovirus myocarditis. , 1990, Immunology.

[7]  G. Hunninghake,et al.  Modulation of interleukin 1 beta gene expression by the immediate early genes of human cytomegalovirus. , 1990, The Journal of clinical investigation.

[8]  C. Malone,et al.  Transactivation of a human cytomegalovirus early promoter by gene products from the immediate-early gene IE2 and augmentation by IE1: mutational analysis of the viral proteins , 1990, Journal of virology.

[9]  P. Ghazal,et al.  Promoter-specific trans activation and repression by human cytomegalovirus immediate-early proteins involves common and unique protein domains , 1990, Journal of virology.

[10]  B. Barrell,et al.  Human cytomegalovirus encodes three G protein-coupled receptor homologues , 1990, Nature.

[11]  S. P. Fodor,et al.  Light-directed, spatially addressable parallel chemical synthesis. , 1991, Science.

[12]  H. Farrell,et al.  Murine anti-cytomegalovirus monoclonal antibodies with autoreactivity. , 1991, Immunology.

[13]  W. Gibson,et al.  Cytomegalovirus homologs of cellular G protein-coupled receptor genes are transcribed , 1991, Journal of virology.

[14]  A. C. Webb,et al.  The immediate early genes of human cytomegalovirus require only proximal promoter elements to upregulate expression of interleukin-1 beta. , 1992, American journal of respiratory cell and molecular biology.

[15]  M. Stinski,et al.  Human cytomegalovirus contains a tegument protein that enhances transcription from promoters with upstream ATF and AP-1 cis-acting elements , 1992, Journal of virology.

[16]  S. P. Fodor,et al.  Multiplexed biochemical assays with biological chips , 1993, Nature.

[17]  N. Kawamura,et al.  Microphthalmia and cerebral atrophy induced in mouse embryos by infection with murine cytomegalovirus in midgestation. , 1993, The American journal of pathology.

[18]  P. Price,et al.  B-cell activation following murine cytomegalovirus infection: implications for autoimmunity. , 1993, Immunology.

[19]  Andrew P. Read,et al.  Waardenburg syndrome type 2 caused by mutations in the human microphthalmia (MITF) gene , 1994, Nature Genetics.

[20]  S. P. Fodor,et al.  Light-generated oligonucleotide arrays for rapid DNA sequence analysis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[21]  A. Ferré-D’Amaré,et al.  Molecular basis of mouse microphthalmia (mi) mutations helps explain their developmental and phenotypic consequences , 1994, Nature Genetics.

[22]  J. Papadimitriou,et al.  A murine cytomegalovirus-neutralizing monoclonal antibody exhibits autoreactivity and induces tissue damage in vivo. , 1994, Immunology.

[23]  Y. Fukunaga,et al.  Stress-induced cell surface expression and antigenic alteration of the Ro/SSA autoantigen. , 1995, Autoimmunity.

[24]  S. P. Fodor,et al.  Using oligonucleotide probe arrays to access genetic diversity. , 1995, BioTechniques.

[25]  J. Corbeil,et al.  Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest , 1995, Journal of virology.

[26]  M. Oldstone,et al.  Virus-induced autoimmune disease , 1996, Current Opinion in Immunology.

[27]  P. A. Peterson,et al.  Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[28]  T. Shenk,et al.  Human cytomegalovirus infection inhibits cell cycle progression at multiple points, including the transition from G1 to S , 1996, Journal of virology.

[29]  James L. Winkler,et al.  Accessing Genetic Information with High-Density DNA Arrays , 1996, Science.

[30]  T. Shenk,et al.  Proteins associated with purified human cytomegalovirus particles , 1996, Journal of virology.

[31]  G. Boire,et al.  Anti-Ro (SSA) antibodies: clinical significance and biological relevance. , 1996, The Journal of rheumatology.

[32]  R. Flower,et al.  The concerted regulation of cPLA2, COX2, and lipocortin 1 expression by IL-1beta in A549 cells. , 1996, Biochemical and biophysical research communications.

[33]  H. Ploegh,et al.  Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Sinclair,et al.  Latent and persistent infections of monocytes and macrophages. , 1996, Intervirology.

[35]  T. Albrecht,et al.  Human cytomegalovirus inhibits cellular DNA synthesis and arrests productively infected cells in late G1. , 1996, Virology.

[36]  J. Xu,et al.  Human cytomegalovirus latent gene expression in granulocyte-macrophage progenitors in culture and in seropositive individuals. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Bogyo,et al.  The Human Cytomegalovirus US11 Gene Product Dislocates MHC Class I Heavy Chains from the Endoplasmic Reticulum to the Cytosol , 1996, Cell.

[38]  R. Flower,et al.  Lipocortin 1 and the control of cPLA2 activity in A549 cells. Glucocorticoids block EGF stimulation of cPLA2 phosphorylation. , 1996, Biochemical pharmacology.

[39]  G. Tuszynski,et al.  The role of thrombospondin-1 in tumor progression and angiogenesis. , 1996, BioEssays : news and reviews in molecular, cellular and developmental biology.

[40]  V. Ferrans,et al.  Pertussis toxin-sensitive G proteins as mediators of the signal transduction pathways activated by cytomegalovirus infection of smooth muscle cells. , 1997, The Journal of clinical investigation.

[41]  P. A. Peterson,et al.  The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. , 1997, Immunity.

[42]  L. Wodicka,et al.  Genome-wide expression monitoring in Saccharomyces cerevisiae , 1997, Nature Biotechnology.

[43]  D. Dittmer,et al.  Human cytomegalovirus infection inhibits G1/S transition , 1997, Journal of virology.

[44]  U. Koszinowski,et al.  A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. , 1997, Immunity.

[45]  O. Mandelboim,et al.  The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells , 1997, Nature.

[46]  T. Shenk,et al.  Use of differential display analysis to assess the effect of human cytomegalovirus infection on the accumulation of cellular RNAs: induction of interferon-responsive RNAs. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[47]  P. Youinou,et al.  Anti-Ro (SSA) and anti-La (SSB) antibodies and complete congenital heart block. , 1997, Annales de medecine interne.

[48]  E. Hwang,et al.  The human cytomegalovirus UL55 (gB) and UL75 (gH) glycoprotein ligands initiate the rapid activation of Sp1 and NF-kappaB during infection , 1997, Journal of virology.

[49]  A. McMichael,et al.  The human major histocompatibility complex class Ib molecule HLA‐E binds signal sequence‐derived peptides with primary anchor residues at positions 2 and 9 , 1997, European journal of immunology.

[50]  K. Fish,et al.  Reactivation of Latent Human Cytomegalovirus by Allogeneic Stimulation of Blood Cells from Healthy Donors , 1997, Cell.

[51]  L. Sun,et al.  Human cytomegalovirus US2 destabilizes major histocompatibility complex class I heavy chains , 1997, Journal of virology.

[52]  R. Hynes,et al.  Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. , 1998, The Journal of clinical investigation.

[53]  J. Coligan,et al.  Recognition of Human Histocompatibility Leukocyte Antigen (HLA)-E Complexed with HLA Class I Signal Sequence–derived Peptides by CD94/NKG2 Confers Protection from Natural Killer Cell–mediated Lysis , 1998, The Journal of experimental medicine.

[54]  J. Bell,et al.  HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C , 1998, Nature.